Key differential aspects of the group of glucagon-like peptide-1 receptor agonist drugs There are several arGLP-1 s approved or under study for the use in DM2: exenatide (exenatide and exenatide LAR or weekly), liraglutide, lixisenatide, dulaglutide, semaglutide, albiglutide (withdrawn from the market), and efpeglenatide (in clinical development)
doi: 10.1056/NEJMoa1903822, 146 Tanofsky-KraffM.MarcusM
Zhou H, Yamada Y, Tsukiyama K, et al
There were no other significant main effects or interactions ( p 0.324)
Efficacy has not been scientifically proven - some products contain high levels of coumarin
Practice Point 4.3.3: GLP-1 RA should not be used in combination with DPP-4 inhibitors